Publication | Closed Access

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

Primary Iga NephropathyGlomerulonephritisRenal FunctionMedicineRandomised Phase 3Iga GlomerulonephritisPharmacologyKidney FailureTargeted-release FormulationAcute Kidney InjuryChronic Kidney DiseaseNephrologyKidney Research